Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 10.10
High: 10.10
Low: 10.10
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Scancell shares slip as losses widen in first half

Thu, 31st Jan 2019 09:48

(Sharecast News) - Cancer immunotherapies developer Scancell Holdings issued its interim results for the six months ended 31 October on Thursday, reporting a loss of £3.24m, widening from £2.02m year-on-year.The AIM-traded firm said its cash balance as at period end was £7.6m, down from £10.3m at the start of the half.It did raise a total of £8.0m net of expenses during the six months, which comprised £1.1m raised in an open offer to shareholders in May, and a placing of £6.9m at the end of the previous financial year.On the operational front, Scancell was granted a patent in Europe for its 'Moditope' technology, which the board said provided "broad protection" for its pipeline of Moditope vaccines.It also expanded its strategic research collaboration with the Rheumatology Unit at the Karolinska Institute, to explore the potential of Moditope to develop multiple immunotherapeutic agents for a range of different cancers.Pre-clinical development was underway with Modi-2, including progress made in the characterisation of specific homocitrullinated peptides for clinical development, the board reported, where there was the potential to address different cancer indications to Modi-1, including tumours with a "particularly immunosuppressive" environment.Scancell and Ichor continued to work with the FDA during the half-year to provide the additional information requested in response to the Investigational New Drug application submitted for the SCIB1 Phase 2 checkpoint inhibitor combination study, the board confirmed.The company also exercised its option to a worldwide commercial licence for the use of Ichor Medical Systems' 'TriGrid 2.0' electroporation delivery system with SCIB1, which would enable Scancell to use the system for its planned Phase 2 checkpoint inhibitor combination study with SCIB1.Since the period ended, the board confirmed the appointments of Dr Samantha Paston as head of research, and Dr Adrian Parry as head of manufacturing."We are pleased to report another six months of progress at Scancell," said chief executive officer Cliff Holloway."The funds raised at the end of the previous financial year and the beginning of this period will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic."Holloway said the company was working closely with Ichor and the FDA to provide the additional information requested for the initiation of its Phase 2 checkpoint inhibitor combination study of SCIB1 in patients with advanced melanoma."With our new hires and recent funding, we believe we are in a strong position to progress our pipeline of immunotherapy products through the next stage of development."As at 0914 GMT, shares in Scancell Holdings were down 4.88% at 7.11p.
More News
2 Jun 2014 11:08

Scancell reports encouraging results of melanoma treatment

Scancell's shares advanced after announcing "encouraging results" from the clinical trial of its SCIB1 ImmunoBody drug for the treatment of stage III/IV melanoma. The phase 1 and 2 trial tested the safety and tolerability of four dose levels of SCIB1 administered intramuscularly using an electropo

Read more
2 Jun 2014 10:39

UK WINNERS & LOSERS: Miners Jump On Upbeat Chinese Data

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday.
-------
FTSE 100 - WINNERS
-------
Anglo American, up 1.9%, Rio Tinto, up 1.7%, Glencore, up 1.4

Read more
2 Jun 2014 08:04

Scancell Rises As It Gets More Good Results From Skin Cancer Treatment Trial

LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC saw its shares rise Monday after it said the latest results from a trial of its SCIB1 ImmunoBodyÒ treatment on skin cancer had shown further evidence of tumour reduction and disease control, enhanced immune responses and "h

Read more
27 May 2014 12:47

Oxford Technology NAV Declines, Appealing VCT Status Withdrawal

LONDON (Alliance News) - Oxford Technology VCT PLC saw its net asset value per share decline in the year to end-February, and said it was appealing the withdrawal of its venture capital trust status. The trust posted a net asset value per share of 65 pence per share, down from 74 pence in t

Read more
15 May 2014 12:46

Scancell Holdings To Present Phase I/II ImmunoBody Trial Data At ASCO

LONDON (Alliance News) - Scancell Holdings PLC said Thursday that it will announce the latest data from its ongoing Phase I/II clinical trial of its SCIB1 ImmunoBody treatment for stage III/IV melanoma will be presented at the American Society of Clinical Oncology meeting in Chicago at the end of

Read more
1 May 2014 13:03

UK MIDDAY BRIEFING: Lloyds Kicks Off Bank Season With Improvement

LONDON (Alliance News) - Lloyds Banking Group kicked off the first-quarter bank earnings season Thursday, reporting that its pretax profit dropped by a third to GBP1.37 billion after last year was buoyed by gains on the sale of government securities.

However, its un

Read more
1 May 2014 11:27

UK WINNERS & LOSERS: Lloyds Atop FTSE 100 Risers; Weir Leads Fallers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.
-------
FTSE 100 - WINNERS
-------
Lloyds Banking Group, up 4.8%. The banking group is the biggest riser in the

Read more
1 May 2014 10:29

Scancell Rises As Long-Time Consultant Joins Its Board

LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC saw its shares rise Thursday after it appointed long-time consultant Dr Sally Adams to its board as development director with immediate effect. In a statement, the company, which is developing immunotherapies to treat

Read more
4 Apr 2014 09:55

Scancell To Announce Phase I/II Of Melanoma Clinical Trial On April 8

LONDON (Alliance News) - Scancell Holdings PLC Friday said that it will announce the results of phase one and two of its clinical trial in patients with stage three and four melanoma at the American Association for Cancer Research annual meeting in San Diego next Tuesday. Scancell Holdings

Read more
21 Mar 2014 09:11

Scancell Holdings Completes Phase 1 Of Melanoma Clinical Trial

LONDON (Alliance News) - Scancell Holdings PLC Friday said it has completed patient dosing with 8mg of SCIB1 ImmunoBody in part one of its on-going phase 1/2 clinical trial in patients with Stage III/IV melanoma. The trial followed a study the firm conducted which showed that a 4mg dose of

Read more
18 Feb 2014 09:19

Scancell Says Patent Application For Cancer Fighting Platform Published

LONDON (Alliance News) - Scancell Holdings PLC Tuesday said its patent application for Moditope has been published, with a view to guarding the platform until 2033 once the patent is granted. In a statement, Scancell said the application for the Modicope platform describes how it uses certa

Read more
11 Feb 2014 09:50

Scancell Gets US Orphan Drug Tag For Metastatic Melanoma Treatment

LONDON (Alliance News) - Scancell Holdings PLC said Tuesday its SCIB1 ImmunoBody metastatic melanoma treatment had been granted orphan drug designation by the US Food and Drug Administration. This designation means that Scancell can qualify for a 50% tax credit for clinical trials of the tr

Read more
11 Feb 2014 09:36

CORRECT: UK MORNING BRIEFING: Shares Open Higher But Barclays Down On Results

Read more

11 Feb 2014 08:32

UK MORNING BRIEFING: Shares Open Higher But Barclays Down On Results

LONDON (Alliance News) - UK shares have opened higher Tuesday ahead of the testimony later in the day by new US Federal Reserve Chair Janet Yellen.

Barclays has said it is in a position to increase its leverage ratio target, despite a loss in its final quarter. Bar

Read more
6 Jan 2014 08:27

Scancell To Boost Moditope Team After Getting Nottingham Grant

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.